CJC-1295 is a synthetic 30-residue analogue of the GHRH 1-29 active fragment with Aib substitutions for DPP-4 resistance. It is offered in two forms: with DAC (drug affinity complex - a maleimide-lysine that covalently binds plasma albumin and extends half-life to days) and without DAC (often called Mod-GRF 1-29, half-life ~30 minutes).

Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that selectively activates the ghrelin / growth hormone secretagogue receptor (GHS-R1a). Unlike the older GHRP-6 and hexarelin, ipamorelin does not stimulate cortisol, prolactin or appetite at standard research doses.

What is the difference between CJC-1295 DAC and CJC-1295 no-DAC?

DAC (drug affinity complex) is a maleimide-lysine modification at position 30 that covalently binds plasma albumin via Cys34. DAC extends the half-life from ~30 minutes (no-DAC) to ~6–8 days, which produces a flatter, continuous GH elevation rather than preserved pulsatile release. Both are unapproved research compounds.

Shop by goal

Popular compounds

Research resources

Certificates of Analysis

CJC-1295 & Ipamorelin: A Research Guide to the GHRH + GHRP Pair

Q: Why are CJC-1295 and ipamorelin studied together?

They act on different receptors with non-overlapping mechanisms - CJC-1295 on the pituitary GHRH receptor, ipamorelin on the ghrelin / GHS-R1a receptor. In pre-clinical work the combination evokes a larger GH pulse than either peptide alone, because GHRH and ghrelin signalling potentiate each other.

Q: Are CJC-1295 and ipamorelin research compounds on this site?

Yes. New-U catalogues CJC-1295 (DAC and no-DAC variants) and ipamorelin as lyophilised reference peptides for laboratory use only, with per-batch Certificates of Analysis. They are sold research use only, not for human consumption.

Short answer: CJC-1295 is a modified GHRH 1-29 analogue (the active fragment of growth hormone-releasing hormone) and ipamorelin is a selective pentapeptide ghrelin mimetic. They act through different receptors - CJC-1295 on the pituitary GHRH receptor, ipamorelin on the GHS-R1a ghrelin receptor - which is why the pair is the most-studied GHRH + GHRP combination in the GH-secretagogue research literature. Neither is approved by any major regulator. New-U catalogues both as lyophilised reference peptides on the HGH / Somatropin shelf: CJC-1295 with DAC, CJC-1295 no-DAC, and ipamorelin - sealed vials, per-batch CoA, research use only.

Search interest in “CJC-1295 ipamorelin” has climbed from roughly 27,000 monthly US queries in late 2025 to over 60,000 per month in 2026 - the fastest-growing combination search in the GH-secretagogue space. This guide explains both molecules, why the pairing has mechanistic logic rather than just marketing logic, the difference between CJC-1295 with and without DAC, and how research-grade reference peptide sits on the New-U catalogue. For the related single-molecule GHRH guide see Tesamorelin: A Research Guide.

Plain-English summary. CJC-1295 and ipamorelin are unapproved research peptides. There are no licensed medicines based on either molecule. New-U sells them as lyophilised reference reagents labelled research use only, not for human consumption , with no dosing or therapeutic guidance. This page is general information, not legal or medical advice; do not use unapproved peptides on people.

Part 1: CJC-1295 - the GHRH analogue

CJC-1295 is built on the 29-amino-acid active fragment of human GHRH - the same 1-29 sequence as sermorelin. The engineering changes are:

Aib substitutions at positions 2 (and in some versions also 8, 15, 27) - replacing native residues with the synthetic amino-isobutyric acid blocks the DPP-4 cleavage site that would otherwise degrade the peptide in minutes.

Optional DAC (Drug Affinity Complex) - a maleimide-lysine residue at position 30 that covalently attaches to the free cysteine (Cys34) of plasma albumin within seconds of administration. Once bound, the entire peptide-albumin complex circulates with albumin’s 19–20 day half-life.

The two variants therefore behave very differently:

Variant Modification Half-life GH profile CJC-1295 no-DAC (“Mod-GRF 1-29”) Aib substitutions only ~30 min Preserved pulsatile GH release - mirrors physiological GHRH CJC-1295 with DAC Aib + maleimide-lysine for albumin binding ~6–8 days Continuous, flatter GH elevation - non-physiological “GH bleed”

The mechanistic distinction matters because endogenous GH is released in pulses every ~3 hours; flat continuous elevation produces different downstream effects than amplified pulses, and the body’s feedback loops (somatostatin, IGF-1 negative feedback) respond differently to each. This is the same trade-off discussed in our tesamorelin guide.

Part 2: Ipamorelin - the selective GHRP

Ipamorelin is a synthetic pentapeptide - just 5 amino acids - with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2 . Despite its short length it is a fully functional growth hormone-releasing peptide (GHRP) : it activates the GHS-R1a ghrelin receptor on the pituitary, triggering a GH pulse through a pathway entirely separate from GHRH.

Ipamorelin was developed by Novo Nordisk in the late 1990s as a successor to the earlier GHRPs (GHRP-6, GHRP-2, hexarelin), specifically to address the side-effect profile of that earlier class:

No cortisol elevation - unlike GHRP-6 and hexarelin, ipamorelin does not significantly raise plasma cortisol at standard research doses.

No prolactin elevation - the cleanest GH-specific signal of any GHRP.

No significant appetite effect - the GHRP-6 hunger spike (driven by ghrelin’s native role) is markedly attenuated.

Selective for GH release - the cleanest signal of the GHRP class on the pituitary somatotroph.

The pentapeptide’s half-life is approximately 2 hours . Ipamorelin never reached approval; Novo Nordisk discontinued its development for commercial reasons in the early 2000s. It remains a widely studied reference compound in the GH-secretagogue research literature.

Why the pair: GHRH + GHRP synergy

GHRH and ghrelin signalling act on different pituitary somatotroph receptors but the downstream GH-release pathways are complementary, not redundant . The result, well-documented in clinical-physiology literature, is that combined GHRH + GHRP stimulation evokes a GH pulse that is meaningfully larger than the sum of either peptide alone. The mechanism is thought to involve simultaneous activation of two parallel intracellular signalling cascades that converge on GH release.

In research practice, the pair has therefore been studied together - a short-half-life GHRH analogue (CJC-1295 no-DAC, or sermorelin) plus a selective GHRP (ipamorelin) - precisely because the combination preserves physiological pulse architecture while delivering a larger amplitude pulse than either alone.

CJC-1295 + Ipamorelin vs tesamorelin vs sermorelin

How the GHRH-family options compare:

Compound Class Receptor Half-life Status Tesamorelin GHRH analogue (full 1-44) GHRH-R ~26 min FDA approved (Egrifta) Sermorelin GHRH fragment (1-29) GHRH-R ~10–20 min Previously approved (Geref, discontinued 2008) CJC-1295 no-DAC GHRH fragment (1-29 + Aib) GHRH-R ~30 min No approval CJC-1295 with DAC GHRH fragment + albumin binder GHRH-R ~6–8 days No approval Ipamorelin GHRP / ghrelin mimetic GHS-R1a ~2 hours No approval

CJC-1295 and ipamorelin as research compounds on this site

On the New-U catalogue, both peptides sit on the HGH / Somatropin shelf as lyophilised reference compounds.

CJC-1295 with DAC - sealed vial, lyophilised, >99% HPLC verified.

CJC-1295 no-DAC (Mod-GRF 1-29) - sealed vial, lyophilised, >99% HPLC verified.

Ipamorelin - sealed vial, lyophilised, >99% HPLC verified.

Standard New-U handling applies to all three: independently verified by Janoshik Analytics and Freedom Diagnostics, per-batch Certificate of Analysis, tracked worldwide delivery, no human-use claims, operated by a Wyoming-registered distributor.

How to verify CJC-1295 and ipamorelin purity

The CoA standard is the same as for the rest of the catalogue. For each compound:

HPLC purity >99% by reversed-phase chromatography.

Mass-spec identity match : CJC-1295 with DAC: ~3,647 Da

CJC-1295 no-DAC: ~3,367 Da

Ipamorelin: ~711 Da (the smallest in the catalogue)

Named third-party lab on the CoA - Janoshik Analytics and Freedom Diagnostics.

Batch number on the CoA matches the vial.

Full walkthrough: How to Read a Certificate of Analysis.

Storage & handling

Both CJC-1295 (either variant) and ipamorelin are stable lyophilised at −20°C for long-term storage. Ipamorelin’s pentapeptide structure is among the most robust in the GH-secretagogue class. Reconstituted material should be stored at 2–8°C and protected from light. Both peptides reconstitute readily in bacteriostatic water; mg-to-mL volume calculation is in our reconstitution calculator and full handling protocol is in How to Store Peptides.

Red flags on CJC-1295 and ipamorelin listings

Walk away from any listing that:

Quotes dosing protocols, mcg-per-injection schedules or muscle-growth promises . Those re-characterise the product as an unlicensed medicine.

Sells a pre-mixed “CJC-1295 + ipamorelin blend” in solution. Lyophilised reference peptides ship dry in sealed vials; blends are formulated medicine territory.

Has no CoA , or shows a generic stock CoA with no batch number tied to your order.

Does not distinguish between CJC-1295 with DAC and without DAC - the two variants are pharmacokinetically very different, and conflating them suggests the seller does not understand the molecule.

Markets ipamorelin as “clinically proven” or “FDA cleared”. It is neither.

Operates from a Telegram-only channel or a newly registered Shopify with no legal entity in the footer.

Quotes a price implausibly far below the rest of the market for verified >99%-pure peptide.

Frequently Asked Questions

What is CJC-1295? A synthetic 30-residue analogue of GHRH 1-29 with Aib substitutions for DPP-4 resistance. Offered in two forms: with DAC (extended half-life via albumin binding) and without DAC (preserved pulsatile GH release).

What is ipamorelin? A synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that selectively activates the GHS-R1a ghrelin receptor. Unlike older GHRPs, ipamorelin does not stimulate cortisol, prolactin or appetite at standard research doses.

Why are CJC-1295 and ipamorelin studied together? They act on different receptors (GHRH-R and GHS-R1a). The two parallel signalling pathways potentiate each other, evoking a larger GH pulse together than either peptide alone.

What is the difference between CJC-1295 with DAC and CJC-1295 no-DAC? DAC is a maleimide-lysine modification that covalently binds plasma albumin, extending half-life from ~30 minutes (no-DAC) to ~6–8 days. DAC produces continuous flat GH elevation; no-DAC preserves the natural pulsatile pattern.

Are CJC-1295 and ipamorelin research compounds on this site? Yes. New-U catalogues CJC-1295 DAC, CJC-1295 no-DAC and ipamorelin as lyophilised reference peptides with per-batch Certificates of Analysis. Sold research use only, not for human consumption.

Primary sources & further reading

U.S. National Library of Medicine - Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295 (Teichman et al., 2006)

PubMed - PubMed: ipamorelin

PubMed - PubMed: CJC-1295

U.S. Food & Drug Administration - FDA (no approval for CJC-1295 or ipamorelin)

External links are provided for research reference only; New-U is not affiliated with the cited organisations and links carry no endorsement either way.

From the Lab - Peptides on LinkedIn & Facebook

Lab-Verified Research CJC-1295 & Ipamorelin

New-U Research Compounds catalogues CJC-1295 (DAC and no-DAC) and ipamorelin as lyophilised reference peptides - sealed 10-vial packs, independently verified by Janoshik and Freedom Diagnostics for >99% HPLC purity, with per-batch Certificates of Analysis. Tracked worldwide delivery. Research use only - not for human consumption.

Research-grade · >99% HPLC purity · COA per lot

Buy Ipamorelin from New-U Research Compounds

Lab-verified by Janoshik Analytical (RP-HPLC + ESI-MS), sealed vials, discreet tracked worldwide shipping. For laboratory research use only — not for human consumption.

Premium research peptides at >99% HPLC-verified purity, third-party tested by Janoshik Analytical with a Certificate of Analysis on every lot. Shipped lab-direct, discreet and cold-chain, worldwide. For laboratory research use only.

Research use only (RUO). All products are sold strictly for laboratory and research purposes — not for human or veterinary consumption. Purchasers must be 21 or older.

Website & business operated by Hilxera Distribution Services LLC. Registered in Wyoming, ID: 2026-001928701.

Research use only — not for human consumption. All products are supplied strictly for laboratory research purposes.

CJC-1295 & Ipamorelin: A Research Guide to the GHRH + GHRP Pair

Part 1: CJC-1295 - the GHRH analogue

Part 2: Ipamorelin - the selective GHRP

Why the pair: GHRH + GHRP synergy

CJC-1295 + Ipamorelin vs tesamorelin vs sermorelin

CJC-1295 and ipamorelin as research compounds on this site

How to verify CJC-1295 and ipamorelin purity

Storage & handling

Red flags on CJC-1295 and ipamorelin listings

Frequently Asked Questions

Related Reading

Primary sources & further reading

From the Lab - Peptides on LinkedIn & Facebook

Lab-Verified Research CJC-1295 & Ipamorelin

Buy Ipamorelin from New-U Research Compounds

Shop

Learn

Company

Support

Ways to Pay

Shop by Compound

Shop by Goal

Ships worldwide